Andrew See

674 total citations
18 papers, 509 citations indexed

About

Andrew See is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Andrew See has authored 18 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Radiation and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Andrew See's work include Prostate Cancer Diagnosis and Treatment (10 papers), Advanced Radiotherapy Techniques (10 papers) and Prostate Cancer Treatment and Research (8 papers). Andrew See is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (10 papers), Advanced Radiotherapy Techniques (10 papers) and Prostate Cancer Treatment and Research (8 papers). Andrew See collaborates with scholars based in Australia, United Kingdom and Canada. Andrew See's co-authors include Sean Bydder, James W. Denham, Jørgen Johansen, C.S. Hamilton, Lloyd M. L. Smyth, Peter C. O’Brien, Gillian Duchesne, Suzanne Wright, R. Hugh Dunstan and Scott Williams and has published in prestigious journals such as International Journal of Radiation Oncology*Biology*Physics, International Journal of Cancer and Radiotherapy and Oncology.

In The Last Decade

Andrew See

18 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew See Australia 10 349 236 185 153 98 18 509
Mark R Storey United States 6 402 1.2× 357 1.5× 147 0.8× 87 0.6× 71 0.7× 8 525
Marketa Skala Australia 13 278 0.8× 158 0.7× 96 0.5× 62 0.4× 54 0.6× 23 392
Eric E. K. Yeoh Australia 11 544 1.6× 348 1.5× 170 0.9× 163 1.1× 141 1.4× 13 720
Masayuki Araya Japan 14 358 1.0× 238 1.0× 174 0.9× 93 0.6× 61 0.6× 39 487
Kirsten Björnlinger Sweden 4 578 1.7× 427 1.8× 177 1.0× 70 0.5× 57 0.6× 7 684
Sylvia van Dyk Australia 15 222 0.6× 240 1.0× 113 0.6× 249 1.6× 51 0.5× 28 606
Tadashi Takenaka Japan 13 126 0.4× 118 0.5× 99 0.5× 160 1.0× 69 0.7× 37 403
Lluís Escudé Spain 12 231 0.7× 257 1.1× 102 0.6× 91 0.6× 41 0.4× 18 398
Petr Paluska Czechia 11 191 0.5× 153 0.6× 87 0.5× 114 0.7× 67 0.7× 35 339
J. Demanes United States 8 270 0.8× 330 1.4× 82 0.4× 301 2.0× 43 0.4× 17 719

Countries citing papers authored by Andrew See

Since Specialization
Citations

This map shows the geographic impact of Andrew See's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew See with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew See more than expected).

Fields of papers citing papers by Andrew See

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew See. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew See. The network helps show where Andrew See may publish in the future.

Co-authorship network of co-authors of Andrew See

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew See. A scholar is included among the top collaborators of Andrew See based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew See. Andrew See is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
See, Andrew, Paul Conway, Mark Frydenberg, et al.. (2024). Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. International Journal of Cancer. 155(7). 1248–1256. 4 indexed citations
2.
See, Andrew, Patrick Bowden, Sree Appu, et al.. (2022). Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial. Radiation Oncology. 17(1). 131–131. 4 indexed citations
3.
Bowden, Patrick, Andrew See, Nathan Lawrentschuk, et al.. (2021). 68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. World Journal of Urology. 39(11). 4117–4125. 1 indexed citations
4.
Smyth, Lloyd M. L., Richard O’Sullivan, Anthony J. Ryan, et al.. (2021). Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. Translational Andrology and Urology. 10(9). 3591–3603. 9 indexed citations
5.
Antón, A., Patrick Bowden, Anthony J. Costello, et al.. (2020). Use of prostate‐specific membrane antigen positron‐emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. British Journal of Urology. 126(4). 433–435. 12 indexed citations
6.
Smyth, Lloyd M. L., et al.. (2019). Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study. Radiation Oncology. 14(1). 223–223. 44 indexed citations
7.
Bowden, Patrick, Andrew See, Mark Frydenberg, et al.. (2019). Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. International Journal of Cancer. 146(1). 161–168. 52 indexed citations
8.
Bowden, Patrick, Andrew See, Michael Dally, & Richard G. Bittar. (2013). Stereotactic radiosurgery for brain and spine metastases. Journal of Clinical Neuroscience. 21(5). 731–734. 5 indexed citations
9.
Barkati, Maroie, Scott Williams, Farshad Foroudi, et al.. (2011). High-Dose-Rate Brachytherapy as a Monotherapy for Favorable-Risk Prostate Cancer: A Phase II Trial. International Journal of Radiation Oncology*Biology*Physics. 82(5). 1889–1896. 96 indexed citations
10.
Joon, Daryl Lim, Michael Chao, Morikatsu Wada, et al.. (2010). The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer. Radiotherapy and Oncology. 97(2). 205–211. 19 indexed citations
11.
Nguyen, Brandon, Daryl Lim Joon, Vincent Khoo, et al.. (2008). Assessing the impact of FDG-PET in the management of anal cancer. Radiotherapy and Oncology. 87(3). 376–382. 81 indexed citations
12.
Middleton, Mark R., Andrew See, Aldo Rolfo, et al.. (2008). Intraprostatic fiducials for image guidance: Workflow implications in a single linac department. Radiography. 14(4). 312–317. 8 indexed citations
13.
14.
Ackerly, Trevor, et al.. (2003). Exploring the effect of marked normal structure volume on normal tissue complication probability. Medical dosimetry. 28(4). 223–227. 3 indexed citations
15.
Duchesne, Gillian, et al.. (2002). Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: Influence of V150 and V200 parameters. Australasian Radiology. 46(4). 384–389. 17 indexed citations
16.
See, Andrew. (2000). Use of Human Epidemiology Studies in Proving Causation. 67(4). 478. 2 indexed citations
17.
See, Andrew, Tomas Kron, Jørgen Johansen, et al.. (2000). Decision‐making models in the analysis of portal films: A clinical pilot study. Australasian Radiology. 44(1). 72–83. 17 indexed citations
18.
Denham, James W., Peter C. O’Brien, R. Hugh Dunstan, et al.. (1999). Is there more than one late radiation proctitis syndrome?. Radiotherapy and Oncology. 51(1). 43–53. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark R Storey Breakdown of academic impact, for papers by Marketa Skala Breakdown of academic impact, for papers by Eric E. K. Yeoh Breakdown of academic impact, for papers by Masayuki Araya Breakdown of academic impact, for papers by Kirsten Björnlinger Breakdown of academic impact, for papers by Sylvia van Dyk Breakdown of academic impact, for papers by Tadashi Takenaka Breakdown of academic impact, for papers by Lluís Escudé Breakdown of academic impact, for papers by Petr Paluska Breakdown of academic impact, for papers by J. Demanes
Rankless by CCL
2026